Close Menu

NEW YORK (GenomeWeb) – In another disappointment for Alzheimer's therapeutic research, Roche announced last week that it has discontinued the Phase III Scarlet Road study involving the monoclonal antibody gantenerumab in pre-dementia patients.

However, Roche is planning to continue to investigate the drug in more advanced Alzheimer's patients with mild dementia in another Phase III trial. In that study, researchers will attempt to accurately diagnose the disease and track patients with mild Alzheimer's with the help of cerebral spinal fluid biomarkers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.